z-logo
open-access-imgOpen Access
Acute reversible kidney injury secondary to bilateral ureteric obstruction
Author(s) -
Michael Organ,
Richard W. Norman
Publication year - 2013
Publication title -
canadian urological association journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.477
H-Index - 38
eISSN - 1920-1214
pISSN - 1911-6470
DOI - 10.5489/cuaj.726
Subject(s) - medicine , malignancy , etiology , cancer , cervical cancer , acute kidney injury , bladder cancer , prostate cancer , cervix , urology , surgery , gastroenterology
Background: Acute reversible kidney injury (ARKI) secondary tobilateral ureteric obstruction (BUO) is a common urological problem.Our goals were to describe the etiology, management andoutcomes of such patients identified between 2006 and 2009 andto compare them with a similar historical study published in 1982.Methods: Chart review was performed on 49 patients with AKRIsecondary to BUO. ARKI was defined as ≥33% decrease in serumcreatinine after intervention. Those with malignant and benigncauses of obstruction were identified and management and outcomedata were collected.Results: Of these 49 patients, 83% had BUO secondary to malignancy,28% of these presenting for the first time. Prevalence ofbladder cancer was increased (p = 0.04) and cervix trended lower(p = 0.07) compared with the earlier study; prostate cancer wasunchanged (p = 0.51). The average survival was 239 days; 90%of patients died within a year after presenting with BUO from amalignant etiology. Compared with the 1982 group, there weretrends towards a decrease in the frequency of retroperitoneal fibrosis(p = 0.08) and an increase in bilateral ureteric calculi (p = 0.16)in the benign group.Conclusions: Patients with ARKI secondary to BUO most likelyhave an underlying malignancy, with almost a third of them beingdiagnosed for the first time. Prevalence of bladder cancer increasedwhile cervical cancer trended lower. The cause for the former isunclear; the latter may be due to aggressive screening. Prostate cancerremained unchanged despite the widespread implementation ofprostate-specific antigen testing. Patients with an underlying malignancydo poorly and those with a newly diagnosed malignancydo worst. Those with ARKI secondary to benign causes did well.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here